#None #New Jersey #ADC technology #ProBio #AbTis

ProBio and AbTis Join Forces to Enhance ADC Development

ProBio, a key player in the global contract research, development, and manufacturing organization (CRDMO) sector, has recently announced a strategic collaboration with South Korea's AbTis Co., Ltd. This exclusive global licensing agreement aims to accelerate the development of next-generation antibody-drug conjugates (ADCs), a notable milestone in the field of oncological therapies.

This partnership will allow AbTis to leverage ProBio's advanced biologics discovery capabilities to develop and commercialize a therapeutic antibody asset targeted at oncology. By utilizing AbTis’ proprietary AbClick® platform for site-specific conjugation in bispecific ADCs, the collaboration seeks to refine and enhance the efficacy of cancer treatments. Allen Guo, CEO of ProBio, highlighted that this alliance exemplifies their strategy of creating differentiated products while empowering partners to advance innovative therapeutic developments.

Under the terms of the agreement, AbTis will gain exclusive rights to a discovery-stage antibody asset originating from ProBio's biologics discovery framework. This initiative underscores a commitment to enhancing the pipeline of bioconjugate therapeutics, with the objective of improving patient outcomes in oncology. With an upfront payment, developmental milestones, and potential royalties on sales, this agreement indicates a robust financial framework supporting the partnership's ambitions.

As stated by Dr. Hyungsuk Choi, CEO of AbTis, this licensing agreement represents a critical advancement for their antibody asset development. They plan to utilize the AbClick® platform effectively to enhance and expedite the ADC development program.

The collaboration reflects ProBio's increasing prominence in fostering innovative biopharmaceuticals through a fusion of discovery expertise and advanced platforms, indicating their ability to facilitate the meticulous crafting of biologics suitable for critical medical applications.

ProBio aims to support biotech and pharmaceutical entities not just in the development and manufacturing of advanced therapies, but also in navigating the regulatory and commercial pathways. Their integrated solutions span various formats, including antibodies, mRNA, and viral vectors while maintaining GMP compliance to ensure robust manufacturing processes.

With a focus on collaboration, ProBio is committed to partnering closely with their clients to enhance innovation cycles and mitigate the risks typically associated with complex developmental tasks. Through this new alignment with AbTis, ProBio looks to translate its discovery capabilities into tangible patient benefits quickly.

This partnership stands to bolster their development efforts in creating advanced ADCs, a therapy class noted for their targeted treatment capabilities against tumors. ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic agents, ensuring minimal damage to healthy tissues while maximizing therapeutic impact on cancer cells.

In conclusion, the exclusive global licensing agreement between ProBio and AbTis signifies an important collaboration in the realm of advanced biotechnological therapies. The implications of this partnership could lead to meaningful advancements in oncology treatments, reflecting a shared commitment to improving the efficacy and reliability of cancer therapies through innovative approaches in drug development.